As an adjunctive treatment, empagliflozin improves glycaemic control in patients with HNF1A-related maturity-onset diabetes ...

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

The use of SGLT2 inhibitors was not associated with a clear increase in overall UTI risk among patients with RA and diabetes.

A study led by the Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.

This comparative effectiveness study found that initiation of sodium-glucose cotransporter-2 inhibitor (SGLT2i) vs glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in individuals with type ...

News, features, and commentary about cancer-related issues ...

The SGLT2 inhibitor empagliflozin (Jardiance) showed some potential for heart failure (HF) prevention in high-risk, ...

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.

SGLT2 inhibitor use was associated with a significantly lower risk for androgen deprivation therapy (ADT) failure and next-generation hormonal agent failure in men with prostate cancer. SGLT2 ...

In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two ...